Cargando…
Usefulness of short-term eltrombopag treatment as a supportive treatment in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia: A report of two cases
Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that increases platelet counts in patients with idiopathic thrombocytopenic purpura and in patients with liver cirrhosis. When cirrhotic patients with thrombocytopenia undergo elective invasive procedures, eltrombopag treatment reduces the...
Autores principales: | KAWAGUCHI, TAKUMI, NAKANO, MASAHITO, SATANI, MANABU, SUMIE, SHUJI, YAMADA, SHINGO, AMANO, KEISUKE, KUROMATSU, RYOKO, SATA, MICHIO |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049767/ https://www.ncbi.nlm.nih.gov/pubmed/24932302 http://dx.doi.org/10.3892/ol.2014.1976 |
Ejemplares similares
-
Total and High Molecular Weight Adiponectin and Hepatocellular Carcinoma with HCV Infection
por: Sumie, Shuji, et al.
Publicado: (2011) -
Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
por: Kawaguchi, Takumi, et al.
Publicado: (2019) -
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012) -
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016) -
Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)